Immunogenic Composition

Abstract

The present application relates to immunogenic compositions comprising a mixture of staphylococcal antigens which combines antigen having different functions, for instance, combinations including a staphylococcal extracellular component binding protein and a staphylococcal transporter protein or a staphylococcal extracellular component binding protein and a staphylococcal regulator of virulence or toxin or a staphylococcal transporter protein and a staphylococcal regulator of virulence or toxin. Vaccines, methods of treatment, uses of and processes to make a staphylococcal vaccine are also described.

1 . An immunogenic composition comprising staphylococcal PNAG and Type 8 capsular polysaccharide or oligosaccharide from  S. aureus.    
     
     
         2 . The immunogenic composition of  claim 1  further comprising Type 5 capsular polysaccharide or oligosaccharide from  S. aureus.    
     
     
         3 . The immunogenic composition of  claim 1  further comprising Type I, and/or Type II and/or Type III capsular polysaccharide or oligosaccharide from  S. epidermidis.    
     
     
         4 . The immunogenic composition of  claim 1  wherein the PNAG is derived from a staphylococcal bacterium.  
     
     
         5 . The immunogenic composition of  claim 1  further comprising a staphylococcal protein or fragment thereof.  
     
     
         6 . The immunogenic composition of  claim 5  wherein the staphylococcal protein or fragment thereof is an extracellular component binding protein selected from the group consisting of laminin receptor, SitC/MntC/saliva binding protein, EbhA, EbhB, Elastin binding protein (EbpS), EFB (FIB), SBI, autolysin, ClfA, SdrC, SdrG, SdrH, Lipase GehD, FnbA, FnbB, Can, ClfB, FbpA, Npase, IsaA/PisA, SsaA, EPB, SSP-1, SSP-2, HBP, Vitronectin binding protein, coagulase, and MAP.  
     
     
         7 . The immunogenic composition of  claim 5  wherein the staphylococcal protein or fragment thereof is a transporter protein selected from the group consisting of Immunodominant ABC transporter, IsdA, IsdB, Mg2+ transporter, SitC and Ni ABC transporter.  
     
     
         8 . The immunogenic composition of  claim 5  wherein the staphylococcal protein or fragment thereof is a toxin or regulatory of virulence selected from the group consisting of alpha toxin (Hla), alpha toxin H35R mutant, and RNA III activating protein (RAP).  
     
     
         9 . The immunogenic composition of  claim 5  comprising 2 or more staphylococcal proteins selected from at least 2 different groups selected from: 
 a) at least one staphylococcal extracellular component binding protein or fragment thereof selected from the group consisting of laminin receptor, EbhA, EbhB, Elastin binding protein (EbpS), EFB (FIB), SBI, autolysin, ClfA, SdrC, SdrG, SdrH, Lipase GehD, FnbA, FnbB, Can, ClfB, FbpA, Npase, IsaA/PisA, SsaA, EPB, SSP-1, SSP-2, Vitronectin binding protein, coagulase and MAP;    b) at least one staphylococcal transporter protein or fragment thereof selected from the group consisting of Immunodominant ABC transporter, IsdA, IsdB, Mg2+ transporter, SitC and Ni ABC transporter; and    c) at least one staphylococcal regulator of virulence, toxin or fragment thereof selected from the group consisting of alpha toxin (Hla), alpha toxin H35R mutant, and RNA III activating protein (RAP).    
     
     
         10 . The immunogenic composition of  claim 1  wherein a staphylococcal polysaccharide is conjugated to a protein carrier.  
     
     
         11 . The immunogenic composition of  claim 1  wherein the PNAG is conjugated to a protein carrier.  
     
     
         12 . The immunogenic composition of  claim 10  wherein the protein carrier comprises a staphylococcal protein or fragment thereof selected from the group consisting of laminin receptor, EbhA, EbhB, Elastin binding protein (EbpS), EFB (FIB), SBI, autolysin, ClfA, SdrC, SdrG, SdrH, Lipase GehD, FnbA, FnbB, Cna, ClfB, FbpA, Npase, IsaA/PisA, SsaA, EPB, SSP-1, SSP-2, HBP, Vitronectin binding protein, coagulase, MAP, Immundominant ABC transporter, IsdA, IsdB, Mg2+ transporter, SitC, Ni ABC transporter, alpha toxin (Hla), alpha toxin H35R mutant and RNA III activating protein (RAP).  
     
     
         13 . The immunogenic composition of  claim 10  wherein the protein carrier is selected from the group consisting of tetanus toxoid, diphtheria toxoid, CRM197,  Haemophilus influenzae  protein D,  Pseudomonas aeruginosa  exoprotein A, pneumococcal pneumolysin and alpha toxoid.  
     
     
         14 . The immunogenic composition of  claim 1  which is capable of generating an effective immune response against both  S. aureus  and  S. epidermidis.    
     
     
         15 . A vaccine comprising the immunogenic composition of  claim 1  and a pharmaceutically acceptable excipient.  
     
     
         16 . A method of making a vaccine comprising the steps of mixing agents to make the immunogenic composition of  claim 1  and adding a pharmaceutically acceptable excipient.  
     
     
         17 . A method of preventing or treating staphylococcal infection comprising the step of administering the vaccine of  claim 15  to a patient in need thereof.  
     
     
         18 . (canceled)